185 related articles for article (PubMed ID: 18797454)
1. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.
Scandlyn MJ; Stuart EC; Somers-Edgar TJ; Menzies AR; Rosengren RJ
Br J Cancer; 2008 Oct; 99(7):1056-63. PubMed ID: 18797454
[TBL] [Abstract][Full Text] [Related]
2. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo.
Somers-Edgar TJ; Scandlyn MJ; Stuart EC; Le Nedelec MJ; Valentine SP; Rosengren RJ
Int J Cancer; 2008 May; 122(9):1966-71. PubMed ID: 18098290
[TBL] [Abstract][Full Text] [Related]
3. In vitro mechanism of action for the cytotoxicity elicited by the combination of epigallocatechin gallate and raloxifene in MDA-MB-231 cells.
Stuart EC; Jarvis RM; Rosengren RJ
Oncol Rep; 2010 Sep; 24(3):779-85. PubMed ID: 20664987
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
[TBL] [Abstract][Full Text] [Related]
5. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
6. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.
Kumar BNP; Puvvada N; Rajput S; Sarkar S; Mahto MK; Yallapu MM; Pathak A; Emdad L; Das SK; Reis RL; Kundu SC; Fisher PB; Mandal M
Mol Pharm; 2018 Jul; 15(7):2698-2713. PubMed ID: 29787277
[TBL] [Abstract][Full Text] [Related]
7. Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF-7/SC Breast Cancer Cells.
To NB; Truong VN; Ediriweera MK; Cho SK
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232636
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
9. Catechins and the treatment of breast cancer: possible utility and mechanistic targets.
Rosengren RJ
IDrugs; 2003 Nov; 6(11):1073-8. PubMed ID: 14600840
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy.
Zhang G; Wang Y; Zhang Y; Wan X; Li J; Liu K; Wang F; Liu K; Liu Q; Yang C; Yu P; Huang Y; Wang S; Jiang P; Qu Z; Luan J; Duan H; Zhang L; Hou A; Jin S; Hsieh TC; Wu E
Curr Mol Med; 2012 Feb; 12(2):163-76. PubMed ID: 22280355
[TBL] [Abstract][Full Text] [Related]
12. Effect of dietary GLA+/-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts.
Kenny FS; Gee JM; Nicholson RI; Ellis IO; Morris TM; Watson SA; Bryce RP; Robertson JF
Int J Cancer; 2001 May; 92(3):342-7. PubMed ID: 11291069
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression.
Li Y; Meeran SM; Tollefsbol TO
Sci Rep; 2017 Aug; 7(1):9345. PubMed ID: 28839265
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells.
Pan X; Zhao B; Song Z; Han S; Wang M
J Pharmacol Sci; 2016 Feb; 130(2):85-93. PubMed ID: 26810571
[TBL] [Abstract][Full Text] [Related]
16. Proliferation of MDA-MB-231 can be suppressed by dimeric-epigallocatechin gallate through competitive inhibition of amphiregulin-epidermal growth factor receptor signaling.
Huang Y; Zhang X; Pang Q; Zhu Q; Liang Q; Zi C; Zhang D; Xiang Z; Wang X; Sheng J
Anticancer Drugs; 2021 Jun; 32(6):647-656. PubMed ID: 33587351
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
[TBL] [Abstract][Full Text] [Related]
19. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
Nguyen Hoang AT; Hoe KL; Lee SJ
PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process.
Sen T; Chatterjee A
Eur J Nutr; 2011 Sep; 50(6):465-78. PubMed ID: 21170718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
